With further validation, circRNA-based assays may become companion diagnostics for immune checkpoint inhibitors and other immunotherapies, complementing or surpassing existing biomarkers such as PD-L1 expression and tumor mutational burden. The gene discussed is CD274; the disease is neoplasm.